Click here to get full coverage on The Technical Signals Behind (INKT) That Institutions Follow - Stock Traders Daily

The Technical Signals Behind (INKT) That Institutions Follow  Stock Traders Daily

The Technical Signals Behind (INKT) That Institutions Follow - Stock Traders Daily

Click here to get full coverage on Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial - Nature

Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial  Nature

Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial - Nature

Click here to get full coverage on AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™  Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

Click here to get full coverage on Innate iNKT cells: from biological insight to clinical impact - Frontiers

Innate iNKT cells: from biological insight to clinical impact  Frontiers

Innate iNKT cells: from biological insight to clinical impact - Frontiers

Click here to get full coverage on The "Off-the-Shelf" Revolution: How iNKT Cell Therapy agenT-797 is Reprogramming the Fight Against Solid Tumors - Oncodaily

The "Off-the-Shelf" Revolution: How iNKT Cell Therapy agenT-797 is Reprogramming the Fight Against Solid Tumors  Oncodaily

The "Off-the-Shelf" Revolution: How iNKT Cell Therapy agenT-797 is Reprogramming the Fight Against Solid Tumors - Oncodaily

Click here to get full coverage on INKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

INKT Financials: Income Statement, Balance Sheet & Cash Flow  Stock Titan

INKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Click here to get full coverage on New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor - Oncodaily

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor  Oncodaily

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor - Oncodaily

Click here to get full coverage on Precision Trading with Mink Therapeutics Inc. (INKT) Risk Zones - Stock Traders Daily

Precision Trading with Mink Therapeutics Inc. (INKT) Risk Zones  Stock Traders Daily

Precision Trading with Mink Therapeutics Inc. (INKT) Risk Zones - Stock Traders Daily

Click here to get full coverage on Functional remodeling of iNKT cells by sulfatide-reactive type II NKT cells reprograms alveolar macrophages to alleviate lung ischemia-reperfusion injury - Nature

Functional remodeling of iNKT cells by sulfatide-reactive type II NKT cells reprograms alveolar macrophages to alleviate lung ischemia-reperfusion injury  Nature

Functional remodeling of iNKT cells by sulfatide-reactive type II NKT cells reprograms alveolar macrophages to alleviate lung ischemia-reperfusion injury - Nature

Click here to get full coverage on MiNK Therapeutics (NASDAQ: INKT) to release Q3 2025 results; conference call scheduled - Stock Titan

MiNK Therapeutics (NASDAQ: INKT) to release Q3 2025 results; conference call scheduled  Stock Titan

MiNK Therapeutics (NASDAQ: INKT) to release Q3 2025 results; conference call scheduled - Stock Titan

Click here to get full coverage on CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment - Oncodaily

CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment  Oncodaily

CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment - Oncodaily

Click here to get full coverage on Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor | Oncogene - Nature

Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor | Oncogene  Nature

Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor | Oncogene - Nature

Click here to get full coverage on New IPF lung data: key immune cells depleted in advanced disease - Stock Titan

New IPF lung data: key immune cells depleted in advanced disease  Stock Titan

New IPF lung data: key immune cells depleted in advanced disease - Stock Titan

Click here to get full coverage on MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress - Oncodaily

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress  Oncodaily

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress - Oncodaily

Click here to get full coverage on iNKT Cell Therapy in 2025: A Novel Paradigm in Cancer Immunotherapy - Oncodaily

iNKT Cell Therapy in 2025: A Novel Paradigm in Cancer Immunotherapy  Oncodaily

iNKT Cell Therapy in 2025: A Novel Paradigm in Cancer Immunotherapy - Oncodaily

Click here to get full coverage on AgenT-797 (iNKT): What Patients Need to Know About This New Cancer Immunotherapy - Oncodaily

AgenT-797 (iNKT): What Patients Need to Know About This New Cancer Immunotherapy  Oncodaily

AgenT-797 (iNKT): What Patients Need to Know About This New Cancer Immunotherapy - Oncodaily

Click here to get full coverage on AgenT-797 (iNKT): Uses in Cancer, Side Effects, Dosages, Expectations, and Clinical Trial Evidence - Oncodaily

AgenT-797 (iNKT): Uses in Cancer, Side Effects, Dosages, Expectations, and Clinical Trial Evidence  Oncodaily

AgenT-797 (iNKT): Uses in Cancer, Side Effects, Dosages, Expectations, and Clinical Trial Evidence - Oncodaily

Click here to get full coverage on MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 815% last week - Yahoo Finance

MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 815% last week  Yahoo Finance

MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 815% last week - Yahoo Finance

Click here to get full coverage on MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer - Yahoo Finance

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer  Yahoo Finance

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer - Yahoo Finance

Click here to get full coverage on INKT Should I Buy - Intellectia AI

INKT Should I Buy - Intellectia AI

Click here to get full coverage on MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages  MarketBeat

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Click here to get full coverage on MiNK Therapeutics Presents Data Supporting Allo-iNKT Cell Therapy In IPF At Keystone Symposia - Nasdaq

MiNK Therapeutics Presents Data Supporting Allo-iNKT Cell Therapy In IPF At Keystone Symposia  Nasdaq

MiNK Therapeutics Presents Data Supporting Allo-iNKT Cell Therapy In IPF At Keystone Symposia - Nasdaq

Click here to get full coverage on MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week - simplywall.st

MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week  simplywall.st

MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week - simplywall.st

Click here to get full coverage on MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - Yahoo Finance

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy  Yahoo Finance

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - Yahoo Finance

Click here to get full coverage on CAR-iNKT: novel immunotherapy for high-risk childhood leukemia - RegMedNet

CAR-iNKT: novel immunotherapy for high-risk childhood leukemia  RegMedNet

CAR-iNKT: novel immunotherapy for high-risk childhood leukemia - RegMedNet

Click here to get full coverage on MiNK Therapeutics Presents New Data of allo-iNKT Cell - GlobeNewswire

MiNK Therapeutics Presents New Data of allo-iNKT Cell  GlobeNewswire

MiNK Therapeutics Presents New Data of allo-iNKT Cell - GlobeNewswire

Click here to get full coverage on MiNK Therapeutics Reports Q3 2025 Results and Accelerates - GlobeNewswire

MiNK Therapeutics Reports Q3 2025 Results and Accelerates  GlobeNewswire

MiNK Therapeutics Reports Q3 2025 Results and Accelerates - GlobeNewswire

Click here to get full coverage on New, 'off-the-shelf' immunotherapy shows promise for treating high-risk childhood leukemia - Medical Xpress

New, 'off-the-shelf' immunotherapy shows promise for treating high-risk childhood leukemia  Medical Xpress

New, 'off-the-shelf' immunotherapy shows promise for treating high-risk childhood leukemia - Medical Xpress

Click here to get full coverage on Potential of Invariant Natural Killer T Cells Spurs Advances in AML - Targeted Oncology

Potential of Invariant Natural Killer T Cells Spurs Advances in AML  Targeted Oncology

Potential of Invariant Natural Killer T Cells Spurs Advances in AML - Targeted Oncology

Click here to get full coverage on INKT's Investigational Cell Therapy Renders Testicular Cancer Patient Disease-free, Stock Soars - Nasdaq

INKT's Investigational Cell Therapy Renders Testicular Cancer Patient Disease-free, Stock Soars  Nasdaq

INKT's Investigational Cell Therapy Renders Testicular Cancer Patient Disease-free, Stock Soars - Nasdaq

Click here to get full coverage on Artificial thymic organoid culture generates functional iPSC-derived CD4+ invariant natural killer T cells - Nature

Artificial thymic organoid culture generates functional iPSC-derived CD4+ invariant natural killer T cells  Nature

Artificial thymic organoid culture generates functional iPSC-derived CD4+ invariant natural killer T cells - Nature

Click here to get full coverage on Trial tests cell therapy to prevent life-threatening transplant complication - Stock Titan

Trial tests cell therapy to prevent life-threatening transplant complication  Stock Titan

Trial tests cell therapy to prevent life-threatening transplant complication - Stock Titan

Click here to get full coverage on Arovella enters clinical stage as FDA clears first CAR-iNKT therapy - BiotechDispatch

Arovella enters clinical stage as FDA clears first CAR-iNKT therapy  BiotechDispatch

Arovella enters clinical stage as FDA clears first CAR-iNKT therapy - BiotechDispatch

Click here to get full coverage on Should I buy MiNK Therapeutics, Inc. (INKT) - Zacks Investment Research

Should I buy MiNK Therapeutics, Inc. (INKT)  Zacks Investment Research

Should I buy MiNK Therapeutics, Inc. (INKT) - Zacks Investment Research

Click here to get full coverage on Arovella reshapes board as CAR-iNKT cell therapy program advances - TipRanks

Arovella reshapes board as CAR-iNKT cell therapy program advances  TipRanks

Arovella reshapes board as CAR-iNKT cell therapy program advances - TipRanks

Click here to get full coverage on MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease - GlobeNewswire

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease  GlobeNewswire

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease - GlobeNewswire

Click here to get full coverage on MiNK Therapeutics Reports Promising Clinical Data and Leadership Expansion Amid Ongoing Development of iNKT Cell Therapies - Quiver Quantitative

MiNK Therapeutics Reports Promising Clinical Data and Leadership Expansion Amid Ongoing Development of iNKT Cell Therapies  Quiver Quantitative

MiNK Therapeutics Reports Promising Clinical Data and Leadership Expansion Amid Ongoing Development of iNKT Cell Therapies - Quiver Quantitative

Click here to get full coverage on Why Is MiNK Therapeutics Stock (INKT) Up 190% Today? - TipRanks

Why Is MiNK Therapeutics Stock (INKT) Up 190% Today?  TipRanks

Why Is MiNK Therapeutics Stock (INKT) Up 190% Today? - TipRanks

Click here to get full coverage on Why Is MiNK Therapeutics Stock (INKT) Down 30% Today? - TipRanks

Why Is MiNK Therapeutics Stock (INKT) Down 30% Today?  TipRanks

Why Is MiNK Therapeutics Stock (INKT) Down 30% Today? - TipRanks

Click here to get full coverage on MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer Meeting - Investing News Network

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer Meeting  Investing News Network

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer Meeting - Investing News Network

Click here to get full coverage on MiNK Therapeutics Extends Cash Runway and Advances Clinical Programs for GVHD and Gastric Cancer - Quiver Quantitative

MiNK Therapeutics Extends Cash Runway and Advances Clinical Programs for GVHD and Gastric Cancer  Quiver Quantitative

MiNK Therapeutics Extends Cash Runway and Advances Clinical Programs for GVHD and Gastric Cancer - Quiver Quantitative

Click here to get full coverage on INKT Stock Price, News & Analysis - Stock Titan

INKT Stock Price, News & Analysis  Stock Titan

INKT Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Allogeneic iPSC-iNKT Cells Tested in Recurrent Head, Neck Cancer - BIOENGINEER.ORG

Allogeneic iPSC-iNKT Cells Tested in Recurrent Head, Neck Cancer  BIOENGINEER.ORG

Allogeneic iPSC-iNKT Cells Tested in Recurrent Head, Neck Cancer - BIOENGINEER.ORG

Click here to get full coverage on Arovella advances novel CAR-iNKT therapy targeting pancreatic and gastric cancers - BiotechDispatch

Arovella advances novel CAR-iNKT therapy targeting pancreatic and gastric cancers  BiotechDispatch

Arovella advances novel CAR-iNKT therapy targeting pancreatic and gastric cancers - BiotechDispatch

Click here to get full coverage on Biotech breakthrough? INKT stock skyrockets 530% after cell therapy cures testicular cancer - The Economic Times

Biotech breakthrough? INKT stock skyrockets 530% after cell therapy cures testicular cancer  The Economic Times

Biotech breakthrough? INKT stock skyrockets 530% after cell therapy cures testicular cancer - The Economic Times

Click here to get full coverage on MiNK Therapeutics Announces New Data Showing MiNK-215 - GlobeNewswire

MiNK Therapeutics Announces New Data Showing MiNK-215  GlobeNewswire

MiNK Therapeutics Announces New Data Showing MiNK-215 - GlobeNewswire

Click here to get full coverage on MiNK Therapeutics Appoints Colonel John B. Holcomb, MD, to Board of Directors - Investing News Network

MiNK Therapeutics Appoints Colonel John B. Holcomb, MD, to Board of Directors  Investing News Network

MiNK Therapeutics Appoints Colonel John B. Holcomb, MD, to Board of Directors - Investing News Network

Click here to get full coverage on MiNK Therapeutics receives NIAID grant to advance iNKT cell therapy for stem cell transplant patients - Oncodaily

MiNK Therapeutics receives NIAID grant to advance iNKT cell therapy for stem cell transplant patients  Oncodaily

MiNK Therapeutics receives NIAID grant to advance iNKT cell therapy for stem cell transplant patients - Oncodaily

Click here to get full coverage on Arovella Files IND for Lead CAR-iNKT Therapy as Cash Reserves Back 2026 Clinical Push - TipRanks

Arovella Files IND for Lead CAR-iNKT Therapy as Cash Reserves Back 2026 Clinical Push  TipRanks

Arovella Files IND for Lead CAR-iNKT Therapy as Cash Reserves Back 2026 Clinical Push - TipRanks

Click here to get full coverage on Making immunotherapy better for children with acute lymphoblastic leukaemia - Cancer Research UK - Cancer News

Making immunotherapy better for children with acute lymphoblastic leukaemia  Cancer Research UK - Cancer News

Making immunotherapy better for children with acute lymphoblastic leukaemia - Cancer Research UK - Cancer News

Click here to get full coverage on MiNK Therapeutics Announces Clinical Trial Success - The Globe and Mail

MiNK Therapeutics Announces Clinical Trial Success  The Globe and Mail

MiNK Therapeutics Announces Clinical Trial Success - The Globe and Mail

Click here to get full coverage on Earnings call transcript: Mink Therapeutics Q2 2025 reveals stock drop amid financial loss - Investing.com

Earnings call transcript: Mink Therapeutics Q2 2025 reveals stock drop amid financial loss  Investing.com

Earnings call transcript: Mink Therapeutics Q2 2025 reveals stock drop amid financial loss - Investing.com

Click here to get full coverage on INKT Forecast — Price Prediction for 2026. Should I Buy INKT? - Intellectia AI

INKT Forecast — Price Prediction for 2026. Should I Buy INKT?  Intellectia AI

INKT Forecast — Price Prediction for 2026. Should I Buy INKT? - Intellectia AI

Click here to get full coverage on MiNK INKT Q2 2025 Earnings Call Transcript - The Globe and Mail

MiNK INKT Q2 2025 Earnings Call Transcript  The Globe and Mail

MiNK INKT Q2 2025 Earnings Call Transcript - The Globe and Mail

Click here to get full coverage on Clinical-Stage Biotech MiNK Therapeutics Sets Q1 Earnings Date: Key iNKT Cell Therapy Updates Expected - Stock Titan

Clinical-Stage Biotech MiNK Therapeutics Sets Q1 Earnings Date: Key iNKT Cell Therapy Updates Expected  Stock Titan

Clinical-Stage Biotech MiNK Therapeutics Sets Q1 Earnings Date: Key iNKT Cell Therapy Updates Expected - Stock Titan

Click here to get full coverage on New ‘off-the-shelf’ immunotherapy shows promise for treating high-risk childhood leukaemia - University of Oxford

New ‘off-the-shelf’ immunotherapy shows promise for treating high-risk childhood leukaemia  University of Oxford

New ‘off-the-shelf’ immunotherapy shows promise for treating high-risk childhood leukaemia - University of Oxford

Click here to get full coverage on MiNK Therapeutics Appoints Dr. John Holcomb as Director - The Globe and Mail

MiNK Therapeutics Appoints Dr. John Holcomb as Director  The Globe and Mail

MiNK Therapeutics Appoints Dr. John Holcomb as Director - The Globe and Mail

Click here to get full coverage on Identification of α-galactosylceramide as an endogenous mammalian antigen for iNKT cells - Rockefeller University Press

Identification of α-galactosylceramide as an endogenous mammalian antigen for iNKT cells  Rockefeller University Press

Identification of α-galactosylceramide as an endogenous mammalian antigen for iNKT cells - Rockefeller University Press

Click here to get full coverage on Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment - Frontiers

Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment  Frontiers

Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment - Frontiers

Click here to get full coverage on Arovella Wins FDA IND Clearance as It Enters Clinical Stage With CAR-iNKT Cancer Therapy - TipRanks

Arovella Wins FDA IND Clearance as It Enters Clinical Stage With CAR-iNKT Cancer Therapy  TipRanks

Arovella Wins FDA IND Clearance as It Enters Clinical Stage With CAR-iNKT Cancer Therapy - TipRanks

Click here to get full coverage on MiNK Therapeutics Enters $50M Sales Agreement with B. Riley - The Globe and Mail

MiNK Therapeutics Enters $50M Sales Agreement with B. Riley  The Globe and Mail

MiNK Therapeutics Enters $50M Sales Agreement with B. Riley - The Globe and Mail

Click here to get full coverage on Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy - Frontiers

Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy  Frontiers

Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy - Frontiers

Click here to get full coverage on Developmentally programmed early-age skin localization of iNKT cells supports local tissue development and homeostasis - Nature

Developmentally programmed early-age skin localization of iNKT cells supports local tissue development and homeostasis  Nature

Developmentally programmed early-age skin localization of iNKT cells supports local tissue development and homeostasis - Nature

Click here to get full coverage on TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells - Science | AAAS

TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells  Science | AAAS

TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells - Science | AAAS

Click here to get full coverage on Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes - Frontiers

Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes  Frontiers

Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes - Frontiers

Click here to get full coverage on Role of CD1d and iNKT cells in regulating intestinal inflammation - Frontiers

Role of CD1d and iNKT cells in regulating intestinal inflammation  Frontiers

Role of CD1d and iNKT cells in regulating intestinal inflammation - Frontiers

Click here to get full coverage on Thymic iNKT single cell analyses unmask the common developmental program of mouse innate T cells - Nature

Thymic iNKT single cell analyses unmask the common developmental program of mouse innate T cells  Nature

Thymic iNKT single cell analyses unmask the common developmental program of mouse innate T cells - Nature

Click here to get full coverage on Unique adipose tissue invariant natural killer T cell subpopulations control adipocyte turnover in mice - Nature

Unique adipose tissue invariant natural killer T cell subpopulations control adipocyte turnover in mice  Nature

INKT

Price Chart

Key Statistics

Technicals

About INKT

Latest News

The Technical Signals Behind (INKT) That Institutions Follow - Stock Traders Daily

Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial - Nature

AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

Advanced Charts

Top Gainers

Top Losers